[Seungkwon Kim, Edaily Reporter] The government’s plan to review health insurance coverage for hair-loss treatments triggered sharp price movements in Korea’s pharmaceutical and biotech sectors on June 15.

Hair-loss drug manufacturers and related platform companies attracted intense buying interest, with several stocks hitting the daily upper price limit. Shares of JW Pharma, Hyundai Pharm, and Samick Pharm each jumped roughly 30%, as investors bet on both near-term growth in prescriptions and the longer-term expansion of the hair-loss treatment market.

JW Pharma: Direct exposure to the hair-loss franchise drives the stock to the daily upper limit

JW Pharma closed at 1,775 won on June 15, up 29.94% from the previous session’s 1,366 won, hitting the daily upper limit. The stock spiked to the limit early in the session and held that level through the close, cementing its position as one of the most prominent beneficiaries of the emerging “hair-loss reimbursement” theme.

The immediate catalyst was the Ministry of Health’s indication that it will formally review expanding National Health Insurance coverage for hair-loss treatments. Since most androgenetic alopecia therapies are currently prescribed on a non-reimbursed basis, investors expect that inclusion on the reimbursement list would ease out-of-pocket costs, drive prescription volume, and broaden the addressable market.

JW Pharma is seen as a direct beneficiary of this shift, thanks to its comprehensive hair-loss portfolio, which includes finasteride-based products such as Monad and Monastar, as well as the dutasteride-based Dutama and related treatments. The company has also been expanding into topical and hair-care lines, rounding out its presence across the hair-loss and scalp-care spectrum.

Sell-side analysts note that while the latest rally is largely driven by policy expectations, the medium-term outlook will depend on how much incremental demand actually materializes. One analyst commented that if reimbursement is implemented, “latent demand in the non-reimbursed market could surface quickly, translating into visible top-line growth for companies already generating meaningful prescription sales in this area.”

Hyundai Pharm, “Mainstream” Minoxidil Brand Re-rated

Hyundai Pharm also hit the daily upper limit, closing at 7,440 won—up 1,710 won, or 29.84%, from the previous day. Along with JW Pharma and other hair-loss stocks, it ranked among the most actively traded shares during the rally.

The surge was driven by renewed interest in Hyundai Pharm’s flagship minoxidil-based hair-loss brand “Minoxyl,” a widely recognized over-the-counter (OTC) treatment available at pharmacies nationwide. The product’s strong brand equity and Hyundai Pharm’s extensive retail distribution network are seen as key advantages at a time when the underlying hair-loss treatment market may be undergoing structural expansion.

Market participants argue that even if reimbursement initially focuses on prescription (ETC) therapies, the policy debate itself helps reposition hair loss from a cosmetic issue to a recognized treatment area. This reframing is expected to lower psychological and financial barriers to care, potentially boosting demand for both prescription and OTC solutions.

An industry official noted that the debate “signals a policy shift toward managing hair loss as a medical condition rather than a purely cosmetic concern,” adding that this could “enlarge the overall market, to the benefit of companies with strong brands and distribution capabilities.” However, the ultimate scope of coverage by drug type and formulation remains uncertain and could materially influence the magnitude of Hyundai Pharm’s upside.

Samick Pharm: Long-acting injection platform gains policy tailwind

Samick Pharm climbed to around 7,700 won, up about 30% and effectively at the daily limit, as investors focused on the company’s long-acting injection (LAI) platform and its potential application to hair-loss treatments.

The company has previously secured a patent for a polymeric microparticle formulation technology using cyclodextrin inclusion complexes, designed to overcome solubility and formulation challenges for poorly water-soluble drugs. This platform is applicable to long-acting depot injections, including those for rheumatic and autoimmune diseases, and is being positioned as a core technology for JAK inhibitor-based therapies such as baricitinib, which is used to treat alopecia areata (patchy hair loss) and other conditions.

By achieving high drug-loading efficiency and controlled release profiles in polymeric microparticles, Samick Pharm aims to address compliance and convenience issues inherent in chronic oral therapies. Long-acting injections are increasingly viewed as an attractive modality for chronic conditions requiring sustained treatment, making the platform strategically relevant as the hair-loss market evolves.

Analysts view the stock’s surge less as a simple “hair loss theme” trade and more as a re-rating of the company’s platform value, underpinned by policy momentum. Still, they caution that key pipeline candidates leveraging the platform remain in the development stage, with clinical and regulatory risks yet to be resolved, implying potential volatility in valuation as milestones are reached.